TWST Stock Risk & Deep Value Analysis
Twist Bioscience Corp
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About TWST Stock
We analyzed Twist Bioscience Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TWST through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TWST Risk Analysis & Red Flags
What Could Go Wrong
Twist Bioscience's aggressive investment in R&D and scaling its platform, particularly in the nascent DNA data storage market, could lead to sustained negative operating cash flow (which was negative in prior quarters) well beyond its Q4 FY2026 adjusted EBITDA breakeven target, forcing further equity dilution (e.g., >10% annual dilution) to fund operations and growth, significantly impacting shareholder value before reaching profitability.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Persistent insider selling by CEO Emily Leproust (16,470 shares sold at $65-$69), Director Melissa A. Starovasnik (2,500 shares sold at $68.00), and other executives, despite ongoing GAAP losses.
- ⚠
Q2 FY2026 EPS miss, indicating continued challenges in translating strong revenue growth into comprehensive GAAP profitability.
- ⚠
Operating cash flow remains negative (as per previous analysis), contradicting prior expectations for 'positive free cash flow in early 2026', suggesting ongoing cash burn.
- ⚠
Absence of specific gross margin or cash flow metrics in recent reports provided, making detailed financial trend analysis difficult for recent performance.
Upcoming Risk Events
- 📅
Q3 FY2026 Earnings Miss or Guidance Reduction (estimated early August 2026): Failure to meet revenue growth expectations or a downward revision of full-year guidance could trigger a significant stock price correction due to investor concerns over execution.
- 📅
Increased Competitive Pressure or Pricing Wars (ongoing 2026-2027): Aggressive pricing or technological advancements from competitors in synthetic biology (e.g., IDT, Codex DNA) could erode Twist's gross margins or slow market share gains, particularly in commoditized segments.
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 15% YoY for two consecutive quarters, indicating significant market saturation or competitive pressure.
- 🚪
Sell if operating cash flow worsens (e.g., negative cash flow from operations exceeds $100M in a single quarter for two consecutive quarters) without clear signs of an inflection point to positive FCF.
- 🚪
Exit if the company announces a new equity offering that dilutes existing shareholders by more than 10% specifically to fund ongoing operational losses rather than strategic growth initiatives.
Unlock TWST Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Twist Bioscience Corp (TWST) Do?
Market Cap
$4.23B
Sector
Healthcare
Industry
Diagnostics & Research
Employees
979
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit Twist Bioscience Corp WebsiteInvestment Thesis
If Twist Bioscience successfully leverages its differentiated silicon-based DNA synthesis platform to capture substantial market share in high-growth synthetic biology applications, expanding gross margins and consistently hitting profitability targets (e.g., adjusted EBITDA breakeven by Q4 FY26), and further validates the commercial viability of its DNA data storage solutions through key partnerships and early revenue, then its market cap can exceed $20 billion (potential 5x) within 3-5 years. This is bullish because the current valuation of ~$4.23 billion does not fully reflect the potential for exponential growth in synthetic biology infrastructure and the massive, long-term opportunity presented by DNA data storage.
Is TWST Stock Undervalued?
Unlock the full AI analysis for TWST
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TWST Price Targets & Strategy
12-Month Target
$105.00
Bull Case
$140.00
Bear Case
$56.00
Valuation Basis
Based on 15x estimated FY27 Sales ($437.5M), implying a $6.56B market cap. This multiple reflects its high growth potential and platform leadership.
Entry Strategy
Dollar-cost average between $60-$70, particularly on dips towards recent support zones or 50-day SMA.
Exit Strategy
Take 50% profit at $100-$110, re-evaluate long-term thesis for remaining position; Stop loss at $55 if growth trajectory fundamentally changes or cash burn accelerates significantly.
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TWST Financially Healthy?
Valuation
P/E Ratio
14.73
Forward P/E
20.12
EV/EBITDA
35.44
PEG Ratio
0.93
Price/Book
3.91
Price/Sales
6.84
Profitability
Gross Margin
52.07%
Operating Margin
-33.90%
Net Margin
-19.85%
Return on Equity
-17.46%
Revenue Growth
17.77%
EPS
$-1.33
Balance Sheet
Current Ratio
3.64
Quick Ratio
3.17
Debt/Equity
0.47
Total Debt
$41.26M
Cash & Equivalents
$316.80M
Cash Flow
Operating Cash Flow
-$65.80M
Free Cash Flow
-$79.20M
EBITDA
-$41.20M
Other
Beta (Volatility)
2.21
Does TWST Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Twist's moat is rooted in its unique silicon-based DNA synthesis platform, which offers significant technical advantages (speed, scale, accuracy) and is protected by a robust IP portfolio. Its durability is expanding as the company extends its offerings (e.g., Complex Genes) and pioneers the nascent DNA data storage market, creating new applications and potential for proprietary standards.
Moat Erosion Risks
- •Emergence of alternative, equally disruptive DNA synthesis technologies that bypass Twist's IP or offer superior cost/performance.
- •Slower-than-expected commercial adoption of DNA data storage, delaying the monetization of a key competitive differentiator and future growth driver.
TWST Competitive Moat Analysis
Sign up to see competitive advantages
TWST Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Neutral
Insider Activity (Form 4)
CEO Emily Leproust sold 16,470 shares ($1.07M-$1.13M) under a 10b5-1 plan, Director Melissa A. Starovasnik sold 2,500 shares ($170K) on May 28, 2026, and Dennis H. Cho had dispositions totaling ~$324K in Feb-Mar 2026. This indicates consistent insider selling.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
Estimated early August 2026 (Q3 FY2026)
Surprise Probability
Medium
Historical Earnings Pattern
Historically volatile, often rallying on strong revenue beats or positive guidance updates, but prone to selling off on wider-than-expected losses or prolonged cash burn.
Key Metrics to Watch
Competitive Position
Top Competitor
IDT (part of Danaher)
Market Share Trend
Gaining
Valuation vs Peers
Trading at a premium Price-to-Sales (P/S) ratio compared to more mature gene synthesis providers, justified by its higher growth rate, proprietary platform, and significant optionality in DNA data storage.
Competitive Advantages
- •Proprietary silicon-based DNA synthesis platform for high throughput and precision
- •Scalability and cost-effectiveness at large volumes
- •Strong intellectual property portfolio protecting core technology
- •First-mover advantage and pioneering efforts in DNA data storage
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TWST Stock Higher?
Near-Term (0-6 months)
- •Q3 FY2026 Earnings Report (estimated early August 2026): Focus on sustained revenue acceleration, gross margin expansion, and updated guidance towards adjusted EBITDA breakeven.
- •Ramp-up of Complex Genes Offering (early access launched May 4, 2026): Successful customer adoption and increasing order volumes for expanded gene synthesis lengths up to 7,000 base pairs, indicating new revenue streams.
Medium-Term (6-18 months)
- •Significant DNA Data Storage R&D Milestone or Major Partnership (Q4 FY26 - Q2 FY27): Announcement of a key technological breakthrough or strategic alliance with a major tech/storage company, validating commercial viability beyond early research.
- •Geographic Expansion or New Platform Feature Launch (FY2027): Successful entry into new high-growth international markets or launch of a novel platform feature that significantly expands addressable applications in synthetic biology.
Long-Term (18+ months)
- •Commercialization and Revenue Generation from DNA Data Storage (FY2028+): First substantial revenue contributions from DNA data storage solutions, positioning Twist as a leader in a potentially transformative market.
- •Platform-as-a-Service (PaaS) Model Maturity and Broad Industry Adoption (FY2028+): Twist's platform becomes an industry standard for gene synthesis across drug discovery, materials science, and industrial biotechnology, driving predictable, high-margin recurring revenue.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TWST?
- ✓
Quarterly revenue growth rate: Watch for sustained acceleration above 20% YoY, particularly from new offerings like Complex Genes.
- ✓
Gross margin trajectory: Monitor for continued expansion towards 55-60%, signaling improving operational efficiency and pricing power.
- ✓
Operating cash flow: Achieving and sustaining positive operating cash flow would be a critical de-risking event and validation of the business model's scalability.
Bull Case Analysis
Sign up free to see the bull case
Competing with TWST
See how Twist Bioscience Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Twist Bioscience Corp TWST | $4.2B | 7.0 | 14.7 | $438.8M | -19.9% | 17.8% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Twist Bioscience Corp Makes Money
Twist Bioscience specializes in creating and selling custom synthetic DNA products and services, primarily leveraging a unique, high-throughput silicon-based platform. This platform allows them to synthesize DNA more efficiently, quickly, and affordably than traditional methods, catering to diverse customers in drug discovery, diagnostics, agriculture, and academic research. They are also investing heavily in pioneering DNA as a long-term data storage medium, developing a potentially revolutionary new market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Twist Bioscience Corp (TWST)?
As of June 2, 2026, Twist Bioscience Corp has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Twist Bioscience Corp?
Twist Bioscience Corp's market capitalization is approximately $4.2B. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does Twist Bioscience Corp use?
TWST is the ticker symbol for Twist Bioscience Corp. The company trades on the NMS.
What is the risk level for TWST stock?
Our analysis rates Twist Bioscience Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TWST?
Twist Bioscience Corp currently has a price-to-earnings (P/E) ratio of 14.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Twist Bioscience Corp's revenue growing?
Twist Bioscience Corp has reported revenue growth of 17.8%. The company is showing strong top-line momentum.
Is TWST stock profitable?
Twist Bioscience Corp has a profit margin of -19.9%. The company is currently unprofitable.
How often is the TWST DVR analysis updated?
Our AI-powered analysis of Twist Bioscience Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TWST (Twist Bioscience Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.